Table S4 from Vγ9Vδ2 T Cells Express an Antitumor Profile Associated with Anti–PD-(L)1 Responses and Activation Defects Restored by Anti-BTN3A in Triple-Negative Breast Cancer

Key Points

Vγ9Vδ2 T cells exhibit an antitumor profile in triple-negative breast cancer.
The activation defects of these T cells can be restored by anti-BTN3A treatment.
Significant differences in immune cell subsets were observed in untreated primary TNBC samples.
Findings suggest the potential of combining anti-PD-(L)1 therapy with BTN3A inhibitors.

We only have this paper's title and publication details.

Analysis reveals immune cell subsets in triple-negative breast cancer, indicating potential for anti-PD-(L)1 therapy.

Percentage of immune cell subsets in untreated primary TNBC, related to Figure 1

No takes yet. Share an insight, caveat, or question.

Fattori et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share